MG
Therapeutic Areas
HiberCell Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HC-7366 | Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1b |
| HC-5404 | Advanced Solid Tumors (enriched for RCC & gastric cancer) | Phase 1a |
| Odetiglucan | Colorectal Cancer Liver Metastasis | Phase 2 |
Leadership Team at HiberCell
SG
Steven Gillis, Ph.D.
Chairman & Acting CEO
CJ
Cindy Jacobs, M.D., Ph.D.
Director
JS
Jim Sullivan, Ph.D.
Director
NB
Nandita Bose, Ph.D.
Chief Development Officer
EL
Eric Lightcap, Ph.D.
Vice President, Translational Science
JI
José Iglesias, M.D.
Clinical Advisor
DB
Daniel Bollag, Ph.D.
Consultant - Regulatory Strategy
RH
Richard Huhn, M.D.
Consultant Senior Medical Director
PR
Philip Rowlands, Ph.D.
Clinical Development Advisor
JA
Julio Aguirre-Ghiso, Ph.D.
Co-Founder